HighTide Therapeutics, Inc., an innovative biopharmaceutical company specializing in the development of multifunctional,...
Shionogi and F2G have reported detailed results from the global Phase 3 OASIS study evaluating investigational oral anti...
The Australian National University (ANU) has been selected as a recipient of the Google.org Impact Challenge: AI for Sci...
QIAGEN and EQT Private Equity agree on an all-cash public takeover offer for all outstanding QIAGEN shares at an off...
La Trobe University is now home to one of the world’s leading biopharmaceutical companies, with the official ope...
Purchase price of $20 per ADS in cash represents an enterprise value of $1.1 billion and an equity value of approximat...
HistoIndex, a pioneer in AI-driven digital pathology for fibrotic diseases, and the Agency for Science, Technology ...
Artificial intelligence is changing how researchers identify therapeutic targets and design molecules, but its lasting v...
Everest Medicines announced on June 26, 2026, that China’s National Medical Products Administration (NMPA) accepte...
Andelyn Biosciences (“Andelyn”), a leading US-based patient-focused cell and gene therapy Contract Developme...
Vitalant, one of the nation’s largest nonprofit blood and biotherapies healthcare organisations, has announced the...
Cell and gene therapies may now be moving faster than the manufacturing networks built to deliver them. The Alliance of...
Germfree, a full-lifecycle engineering and manufacturing partner for mission-critical environments across life sciences,...
Terumo Blood and Cell Technologies (Terumo BCT), a medical technology company advancing blood- and cell-based therapies ...
The Association for the Advancement of Blood & Biotherapies (AABB) has published a special supplemental issue of its...
Neuraxpharm Group and Minoryx Therapeutics have announced that the European Commission has granted marketing authorisati...
As Asia Pacific economies grapple with ageing populations, shrinking workforces and rising healthcare expenditure, they ...
IASO Biotechnology has received US Food and Drug Administration clearance for the Investigational New Drug application o...
Accro Bioscience and Fosun Pharma are preparing to advance AC-201 into a Phase II/III clinical trial in China for non-se...
Ascletis Pharma has initiated a US Phase I clinical study of ASC36 oral tablets, an investigational amylin receptor pept...
For children born with cleft lip and palate, repairing gaps in the jawbone often means waiting until they are 10 to 12 y...
Everest Medicines has announced that China’s National Medical Products Administration has accepted the Biologics L...
Scientists from Nanyang Technological University (NTU), Singapore have developed microscopic peptide droplets that deliv...
Singapore has become the first ASEAN country to provide government subsidies for eligible patients receiving vutrisiran ...
Researchers from the National University of Singapore (NUS) Medicine and China's Tianjin Medical University General Hosp...
